Table 6 Accumulated dose volume histograms (DVH) over the entire breathing cycle. All plans were renormalized to GTV median dose D50
PTVITV(i) | PTVVH(ii) | WCSCITV(iii) | WCSGTV(iv) | |||
|---|---|---|---|---|---|---|
motion effect (Wilcoxon’s) | Mean ± SD (range) | Mean ± SD (range) | Mean ± SD (range) | Mean ± SD (range) | (i) vs.(ii) vs.(iii) vs.(iv) p-value < 0.05 | |
GTV | ||||||
D98 (Gy) | 50.8 ± 0.6 (49.6–51.7) | 51.0 ± 1.3 (48.5–52.6) | 50.4 ± 1.3 (48.6–52.5) | 50.3 ± 1.1 (47.4–51.5) | ||
p-value | 0.003 | 1.000 | 0.003 | 0.92 | ||
D50 (Gy) | 54.0 ± 0.2 (53.7–54.4) | 53.8 ± 0.3 (53.1–54.2) | 54.0 ± 0.2 (53.7–54.3) | 53.9 ± 0.2 (53.4–54.3) | (ii)-(iv) | |
p-value | 0.267 | 0.022 | 0.092 | 0.092 | ||
D2 (Gy) | 56.4 ± 0.7 (55.0–57.7) | 55.8 ± 0.8 (55.0–57.4) | 56.7 ± 1.0 (54.9–58.7) | 56.5 ± 0.7 (55.6–58.0) | ||
p-value | < 0.01 | < 0.01 | < 0.01 | < 0.01 | ||
Chest Wall | ||||||
V30Gy (cm3) | 8.8 ± 8.4 (0.0–27.2) | 8.7 ± 6.9 (0.0–21.2) | 7.3 ± 5.5 (0.0–17.5) | 7.1 ± 5.3 (0.0–17.5) | ||
p-value | 0.01 | 0.02 | 0.02 | 0.02 | ||
Lung | ||||||
V5Gy (cm3) | 16.5 ± 5.8 (7.7–30.0) | 17.3 ± 5.1 (8.0–26.7) | 16.8 ± 5.7 (7.5–28.7) | 16.1 ± 5.6 (7.2–28.3) | (ii)-(iv) | |
p-value | 0.01 | 0.04 | 0.02 | 0.03 | ||
V20Gy (cm3) | 6.7 ± 3.3 (2.7–13.5) | 6.8 ± 3.1 (2.9–12.0) | 6.3 ± 3.0 (2.6–11.9) | 6.2 ± 3.1 (2.5–12.2) | (ii)-(iii); (ii)-(iv) | |
p-value | < 0.01 | < 0.05 | 0.02 | < 0.01 | ||
MLD (Gy) | 4.0 ± 1.6 (1.8–7.2) | 4.1 ± 1.3 (1.9–6.1) | 3.9 ± 1.4 (1.8–6.3) | 3.8 ± 1.4 (1.7–6.3) | (ii)-(iv) | |
p-value | 0.01 | 0.01 | < 0.01 | < 0.01 | ||